Drugs / Sindilizumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06764680 | Dec 2024 → Jun 2026 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06219980 | Dec 2023 → Dec 2025 overdue | — | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05782426 | Mar 2023 → Jan 2024 | non-small cell lung carcinoma | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06902038 | Mar → Dec 2025 overdue | HIV infectious disease | Jun Chen, MD | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sindilizumab | “neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles.” NCT06219980 ↗3“Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles.” NCT05782426 ↗ “100mg of sindilizumab, was dissolved in 50ml normal saline, q3w was administered ×2” NCT06902038 ↗ |
| Action | Inhibit | “PD-1 inhibitor” NCT06902038 ↗ |
| Route | Intravenous | “200mg. ivgtt. d1. q4w” NCT06764680 ↗ |